Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

PSI Announces Collaboration With Synta Pharmaceuticals for the GALAXY-2 Phase III Non-Small Cell Lung Cancer Trial



  PSI Announces Collaboration With Synta Pharmaceuticals for the GALAXY-2
  Phase III Non-Small Cell Lung Cancer Trial

Business Wire

ZUG, Switzerland -- March 5, 2013

PSI CRO, a full-service contract research organization, announced today that
the company has been selected by Synta Pharmaceuticals to conduct their
GALAXY-2 trial, a Randomized Phase III Study of Ganetespib in Combination with
Docetaxel versus Docetaxel Alone in Patients with Advanced Non-Small-Cell Lung
Cancer. PSI is currently initiating this 500-patient study across 15+
countries.

PSI has been conducting clinical trials in oncology since 1994. Lung cancer
represents one of the central oncological indications in the PSI portfolio.
PSI’s commitment to thorough feasibility and “go-the-extra-mile“ project
management, has secured PSI’s reputation for high quality and on-time delivery
in the area of lung cancer.

About Synta Pharmaceuticals: Synta Pharmaceuticals, located in Lexington, MA,
is a biopharmaceutical company focused on discovering, developing, and
commercializing novel pharmaceutical products for extending and enhancing the
lives of patients with severe medical conditions, including cancer and chronic
inflammatory disease. Synta has a unique chemical compound library, an
integrated discovery engine, and a pipeline of small molecule drug candidates
with novel chemical structures and distinct mechanisms of action. All drug
candidates were invented internally by Synta scientists using their compound
library and discovery capabilities. www.syntapharma.com

About PSI CRO AG: PSI is a privately-held, full-service contract research
organization (CRO), operating globally with 1,200 employees worldwide. PSI
positions itself as a no-nonsense CRO capable of saving pharmaceutical
sponsors millions of development dollars by consistently meeting clinical
trial timelines. PSI’s global reach supports the operations of clinical trials
across multiple countries and continents. Global headquarters are located in
Zug, Switzerland at 113a Baarerstrasse 6300. www.psi-cro.com

Contact:

PSI Inquiries to:
PSI CRO AG
Myrna Sanchez, +41 41 228 10 00
Corporate Headquarters
contact@psi-cro.com
or
Media Inquiries:
Ripple Effect Communications
Valerie Harden, +1 617-536-8887
valerie@rippleeffectpr.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement